healthcare-thumbnail.png

Intrahepatic Cholangiocarcinoma Market Research Report - Size, Share, Growth, and Trend Analysis | Forecast (2025 - 2030)

Intrahepatic Cholangiocarcinoma Market (2025-2030)

Intrahepatic Cholangiocarcinoma (ICC) is a rare form of liver cancer originating in the bile ducts inside the liver. The market encompasses various treatment modalities, including chemotherapy, immunotherapy, targeted therapies, and surgical interventions aimed at managing this aggressive malignancy. Due to the poor prognosis and late diagnosis of ICC, treatment options remain limited, making this market crucial for oncology innovation.

 

Disruptive Impact and Opportunities:

The ICC market presents significant opportunities for disruptive innovation, primarily driven by the introduction of targeted therapies and immuno-oncology drugs. Emerging therapies offer new, easy, and safe treatment alternatives with potential for enhanced efficacy. The market is expected to see large growth due to the high unmet medical need, especially in advanced stages of the disease. Additionally, improved diagnosis techniques and combination therapy regimens could significantly increase treatment success, making a substantial impact in improving patient survival rates.

Emerging Drugs:

  • Derazantinib (Basilea Pharmaceutica)
  • Durvalumab (AstraZeneca)

Marketed Drugs:

  • Cisplatin (Platinol)
  • Gemcitabine (Gemzar)

Key Companies:

  • Basilea Pharmaceutica
  • AstraZeneca
  • Delcath Systems Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • Syndax Pharmaceuticals
  • Hutchison Medipharma Limited
  • Medivir
  • Newish Technology (Beijing) Co., Ltd.
  • Relay

 

Market Segmentation:

 

By Type

  • Localized Intrahepatic Cholangiocarcinoma
  • Advanced Intrahepatic Cholangiocarcinoma
    • Stage II
    • Stage III
    • Stage IV

By Treatment Type

  • Chemotherapy
    • Gemcitabine-based Regimens
    • Cisplatin-based Regimens
    • Others
  • Immunotherapy
    • Immune Checkpoint Inhibitors
    • Cancer Vaccines
  • Targeted Therapy
    • EGFR Inhibitors
    • FGFR Inhibitors
    • IDH Inhibitors
  • Surgical Intervention
    • Liver Resection
    • Liver Transplantation
  • Radiation Therapy
    • External Beam Radiation
    • Brachytherapy
  • Combination Therapy
    • Chemotherapy + Immunotherapy
    • Chemotherapy + Targeted Therapy
    • Others

What’s in It for You?

  • Informed decision-making: Gain insights into emerging therapies and marketed solutions for better strategic planning.
  • Growth opportunities: Identify high-growth areas driven by novel treatments like targeted therapies and immunotherapies.
  • Competitive landscape: Understand the current market dynamics, including key players and their strategies.
  • Investment insights: Find potential investment opportunities and partnerships in innovative companies leading the market.
  • Market trends: Track emerging trends in drug development, regulatory approvals, and clinical outcomes to stay ahead of the curve.
  1. Intrahepatic Cholangiocarcinoma Market - Executive Summary
    1. Introduction
    2. Objectives
    3. Key Findings
      1. Market Size 2025 & 2030: By Key Country (10MM)
      2. Global Market Size 2025 & 2030: By Key Segment
      3. Key Investments & Startup Analysis
    4. Research Methodology
  2. Understanding the Disease
    1. Disease Overview
    2. Classification
    3. Signs and Symptoms
    4. Risk Factors
    5. Causes
    6. Disease Biology & Digital Innovations
    7. Stages & Staging System
    8. Diagnostic Algorithm
    9. Current Treatment Practices & Algorithm
    10. Current Standard of Care and Treatment Gaps
    11. Patient Demographics and Treatment Pathways
  3. Guidelines
  4. Unmet Needs
  5. Epidemiology and Patient Population
    1. Epidemiology Key Findings
    2. Assumptions and Rationale: 10MM
    3. Epidemiology Scenario: 10MM
    4. U.S. Epidemiology Scenario
    5. EU-5 Epidemiology
      1. U.K. Epidemiology Scenario
      2. Germany Epidemiology Scenario
      3. France Epidemiology Scenario
      4. Italy Epidemiology Scenario
      5. Spain Epidemiology Scenario
    6. Japan Epidemiology Scenario
    7. China Epidemiology Scenario
    8. Australia Epidemiology Scenario
    9. India Epidemiology Scenario   
  6. Real-world Data & Real-world Evidence
  7. Drug Development Landscape
    1. Existing Key Drug Candidate Profiles/ Marketed Therapies
    2. Competitive Analysis and Differentiation
    3. Overview of Similar/Competing Drugs in Clinical Trials
    4. Future Trends and Emerging Drugs
  8. Regulatory Strategy and Potential Challenges
    1. Regulatory Pathways in Key Markets
    2. Anticipated Regulatory Hurdles and Mitigation Strategies
    3. Case Studies in Oncology Drug Regulation
    4. Impact of Potential Changes to Regulatory Framework
  9. Commercial Landscape
    1. Market Size & Growth Rates
    2. Key Approvals & Anticipated Loss of Exclusivity
    3. PESTLE & Porter’s Five Forces Analysis
    4. Market Shares, Positioning/Ranking
    5. Market Drivers
    6. Identification of Threats
    7. Digital Evolution in Commercialization
  10. Market Segmentation
  11. Pricing, Reimbursement, and Access
    1. Competitive Pricing Analysis
    2. Reimbursement Landscape and Challenges
    3. Strategies for Market Access and Equity
    4. Patient Spending/Expenditure Analysis
  12. Future Trends, Disruptions, and Opportunities
    1. Analysis of Emerging Trends
    2. Technological Impact
    3. Impact of Potential Market Disruptors
    4. Opportunities for Future Development and Expansion
    5. Considerations for Investment Opportunities
  13. Global Market Dynamics
    1. Regional Regulatory Disparities
    2. Cross-Border Partnership Strategies
    3. Global Supply Chain Dynamics
    4. Case Studies: Success and Failure in Global Markets
    5. Strategies for Global Expansion and Localization
  14. Company Profiles

 

 

Download Sample

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Analyst Support

Every order comes with Analyst Support.

Customization

We offer customization to cater your needs to fullest.

Verified Analysis

We value integrity, quality and authenticity the most.